Abstract
Recently a possible cross talk about the relationship between p53 and beta-catenin has been suggested by the observation that colorectal cancers accumulating beta-catenin (as a result of APC mutations) also exhibit high frequency p53 mutations. Our aim was to evaluate the pattern of both the proteins and match these with the morphological changes in colorectal carcinogenesis. Immunohistochemical patterns of p53 and beta catenin were studied using the natural carcinogenetic model of malignant colorectal sporadic adenoma in 27 formalin-fixed paraffinembedded polyps. We found a progressive increase of p53 and beta-catenin staining from normal, to dysplastic, and to cancerous epithelium. We noted, in dysplastic and cancerous epithelium, but not in normal tissue, the translocation of beta-catenin from the cytoplasm to the nucleus, and in dysplastic epithelium, a significant correlation between p53 over expression and betacatenin patterns. Beta-catenin cytoplasmic accumulation seemed to drive p53 over expression already in the early stages of carcinogenesis, while nuclear beta-catenin translocation appeared to be related to a pattern of invasion of neoplastic cells.
Keywords: colorectal adenoma, immunohistochemistry, p53, beta-catenin
Current Pharmaceutical Design
Title: P53 and Beta-Catenin in Colorectal Cancer Progression
Volume: 9 Issue: 24
Author(s): Anna Maria Valentini, Michele Pirrelli, Letizia Renna, Raffaele Armentano and Maria Lucia Caruso
Affiliation:
Keywords: colorectal adenoma, immunohistochemistry, p53, beta-catenin
Abstract: Recently a possible cross talk about the relationship between p53 and beta-catenin has been suggested by the observation that colorectal cancers accumulating beta-catenin (as a result of APC mutations) also exhibit high frequency p53 mutations. Our aim was to evaluate the pattern of both the proteins and match these with the morphological changes in colorectal carcinogenesis. Immunohistochemical patterns of p53 and beta catenin were studied using the natural carcinogenetic model of malignant colorectal sporadic adenoma in 27 formalin-fixed paraffinembedded polyps. We found a progressive increase of p53 and beta-catenin staining from normal, to dysplastic, and to cancerous epithelium. We noted, in dysplastic and cancerous epithelium, but not in normal tissue, the translocation of beta-catenin from the cytoplasm to the nucleus, and in dysplastic epithelium, a significant correlation between p53 over expression and betacatenin patterns. Beta-catenin cytoplasmic accumulation seemed to drive p53 over expression already in the early stages of carcinogenesis, while nuclear beta-catenin translocation appeared to be related to a pattern of invasion of neoplastic cells.
Export Options
About this article
Cite this article as:
Valentini Maria Anna, Pirrelli Michele, Renna Letizia, Armentano Raffaele and Caruso Lucia Maria, P53 and Beta-Catenin in Colorectal Cancer Progression, Current Pharmaceutical Design 2003; 9 (24) . https://dx.doi.org/10.2174/1381612033454216
DOI https://dx.doi.org/10.2174/1381612033454216 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Conditionally Replicating Adenoviruses for Cancer Treatment
Current Cancer Drug Targets FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Is it Possible to Reduce the Incident of Colorectal Cancer by Modifying Diet and Lifestyle?
Current Cancer Therapy Reviews Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Copper Compounds in Anticancer Strategies
Current Medicinal Chemistry The Molecular Machinery Regulating Apoptosis Signal Transduction and its Implication in Human Physiology and Pathophysiologies
Current Molecular Medicine Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry Recent Advances in Structural Modification Strategies for Lead Optimization of Tyrosine Kinase Inhibitors to Explore Novel Anticancer Agents
Current Medicinal Chemistry Integrative Analysis of miRNA-mediated Competing Endogenous RNA Network Reveals the lncRNAs-mRNAs Interaction in Glioblastoma Stem Cell Differentiation
Current Bioinformatics Esophagogastric Cancer: Integration of Targeted Therapies into Systemic Chemotherapy
Current Cancer Drug Targets Preparation of β-CD-Vitexin Microspheres and their Effects on SW480 Cell Proliferation
Current Drug Delivery Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma
Current Pharmaceutical Design Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Knockdown of LRCH4 Remodels Tumor Microenvironment Through Inhibiting YAP and TGF-β/Smad Signaling Pathway in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Current Insight into Novel Delivery Approaches of Resveratrol for Improving Therapeutic Efficacy and Bioavailability with its Clinical Updates
Current Pharmaceutical Design Genomic and Epigenomic Instability, Fragile Sites, Schizophrenia and Autism
Current Genomics Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery